Association between PIK3CA activating mutations and outcomes in early-stage invasive lobular breast carcinoma treated with adjuvant systemic therapy
By:
References
- Martinez V, Azzopardi JG. Invasive lobular carcinoma of the breast: incidence and variants. Histopathology 1979; 3: 467–88. doi: 10.1111/j.1365-2559.1979.tb03029.x
- Yoder BJ, Wilkinson EJ, Massoli NA. Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast. Breast J 2007; 13: 172–79. doi: 10.1111/j.1524-4741.2007.00393.x
- Korkola JE, DeVries S, Fridlyand J, Hwang ES, Estep AL, Chen YY, et al. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 2003; 63: 7167–75. PMID: 14612510
- Cleton-Jansen AM. E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res 2002; 4: 5–8. doi: 10.1186/bcr416
- Coradini D, Pellizzaro C, Veneroni S, Ventura L, Daidone MG. Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. Br J Cancer 2002; 87: 1105–11. doi: 10.1038/sj.bjc.6600556
- Toikkanen S, Pylkkanen L, Joensuu H. Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer 1997; 76: 1234–40. doi: 10.1038/bjc.1997.540
- Silverstein MJ, Lewinsky BS, Waisman JR, Gierson ED, Colburn WJ, Senofsky GM, et al. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer 1994; 73: 1673–7. doi: 10.1002/1097-0142(19940315)73:6<1673::aid-cncr2820730620>3.0.co
- Molland JG, Donnellan M, Janu NC, Carmalt HL, Kennedy CW, Gillet DJ. Infiltrating lobular carcinoma – a comparison of diagnosis, management and outcome with infiltrating duct carcinoma. Breast 2004; 13: 389–96. doi: 10.1016/j.breast.2004.03.004
- Ashikari R, Huvos AG, Urban JA, Robbins GF. Infiltrating lobular carcinoma of the breast. Cancer 1973; 31: 110–6. doi: 10.1002/1097-0142(197301)31:1<110::aid-cncr2820310115>3.0.co;2-v
- Tubiana-Hulin M, Stevens D, Lasry S, Guinebretiere JM, Bouita L, Cohen-Solal C, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncology 2006; 17: 1228–33. doi: 10.1093/annonc/mdl114
- Cristofanilli M, Gonzales-Angulo A, Sneige N, Kau S-W, Broglio K, Theriault RL, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005; 23: 41–8. doi: 10.1200/JCO.2005.03.111
- Mathieu MC, Rouzier R, Llombart-Cussac A, Sideris L, Koscielny S, Travagli JP, et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 2004; 40: 342–51. doi: 10.1016/j.ejca.2003.08.015
- Du Toit RS, Locker AP, Ellis IQ, Elston CW, Nicholson RI, Robertson JF, et al. An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol 1991; 17: 251–7. PMID: 1646127
- Rakha EA, EL-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer 2008; 44: 73–83. doi: 10.1016/j.ejca.2007.10.009
- Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, et al. Genomic characterization of primary invasive lobular breast cancer. J Clinical Oncol 2016; 34: 1872–81. doi: 10.1200/JCO.2015.64.0334
- Zardavas D, Te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, et al. Tumor PIK3CA genotype and prognosis in early-stage breast cancer: a pooled analysis of individual patient data. J Clin Oncol 2018; 36: 981–90. doi: 10.1200/JCO.2017.74.830
- Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, et al. Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1–98 trial. J Clin Oncol 2015; 33: 2772–9. doi: 10.1200/JCO.2015.60.8133
- Luen SJ, Asher R, Lee CK, Savas P, Kammler R, Dell”Orto P, et al. Association of somatic driver alterations with prognosis in postmenopausal, hormone receptor-positive, HER2-negative early breast cancer: a secondary analysis of the BIG 1–98 randomized clinical trial. JAMA Oncol 2018; 4: 1335–43. doi: 10.1001/jamaoncol.2018.1778
- Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histopathological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 1991; 19: 403–10. doi: 10.1111/j.1365-2559.1991.tb00229.x
- Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010; 134: e48–72. doi: 10.1200/JCO.2009.25.6529
- Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor-2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997–4013. doi: 10.1200/JCO.2013.50.9984
- Dowsett M, O Nielsen T, A”Hern R, BartletT J, Coombes RC, Cuzick J, et al. Assessment of Ki-67 in breast cancer: recommendations from the International Ki-67 in Breast Cancer Working Group. J Natl Cancer Inst 2011; 103: 1656–64. doi: 10.1093/jnci/djr393
- Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26: 259–71. doi: 10.1093/annonc/mdu450
- Samuels Y, Wang Z, Bardeli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutation of the PIK3CA gene in human cancers. Science 2004; 304: 554. doi: 10.1126/science.1096502
- Pramod N, Nigam A, Basree M, Mawalkar R, Mehra S, Shinde N, et al. Comprehensive review of molecular mechanisms and clinical features of invasive lobular cancer. Oncologist 2021; 26: e943–53. doi: 10.1002/onco.13734
- Johansson A, Yu NY, Iftimi A, Tobin NP, vant Veer L, Nordenskjold B, et al. Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature. Int J Cancer 2022; 150: 2072–82. doi: 10.1002/ijc.33969
- Griffith OL, Spies NC, Anurag M, Griffith M, Luo J, Tu D, et al. The prognostic effects of somatic mutations in ER-positive breast cancer. Nat Commun 2018; 9: 3476. doi: 10.1038/s41467-018-05914-x
- McCart Reed AE, Kalinowski L, Simpson PT, Lakhani SR. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. Breast Cancer Res 2021; 23: 6. doi: 10.1186/s13058-020-01384-6
- McCart Reed AE, Lal S, Kutasovic JR, Wockner L, Robertson A, de Luca XM, et al. LobSig is a multigene predictor of outcome in invasive lobular carcinoma. NPJ Breast Cancer 2019; 5: 18. doi: 10.1038/s41523-019-0113-y
- Metzger FO, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, et al. Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1–98 trial. J Clin Oncol 2015; 33: 2772–79. doi: 10.1200/JCO.2015.60.813
- Lopez-Knowles E, Segal CV, Gao Q, Garcia-Murillas I, Turner NC, Smith I, et al. Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition. Breast Cancer Res 2014; 16: R68. doi: 10.1186/bcr3683
- Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbeck V, Larsimont D, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 2010; 107: 10208–13. doi: 10.1073/pnas.0907011107
- Whyte DB, Holbeck SL. Correlation of PIK3CA mutations with gene expression and drug sensitivity in NCI-60 cell lines. Biochem Biophys Res Commun 2006; 340: 469–75. doi: 10.1016/j.bbrc.2005.12.025
Language: English
Page range: 220 - 228
Submitted on: Feb 13, 2023
Accepted on: May 18, 2023
Published on: Jun 21, 2023
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2023 Domen Ribnikar, Valentina Jeric Horvat, Ivica Ratosa, Zachary W Veitch, Biljana Grcar Kuzmanov, Srdjan Novakovic, Erik Langerholc, Eitan Amir, Bostjan Seruga, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.